Drug intelligence / Profile preview

GPN01530-2

Development stage: Unknown
Lead developer: Grand Pharmaceutical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GPN01530-2 is a radiopharmaceutical drug conjugate (RDC) targeting Fibroblast Activation Protein (FAP), currently under development by Grand Pharma (宏遠藥業) with early R&D support from Serilink Biotechnology. The agent is designed for the diagnostic imaging and evaluation of solid tumors, leveraging the high expression of FAP on cancer-associated fibroblasts (CAFs) within the tumor microenvironment. GPN01530-2 has received Fast Track Designation from the U.S. FDA and is being evaluated in Phase 1/2 clinical trials to assess its safety and efficacy as a diagnostic tool for visualizing various solid malignancies.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on GPN01530-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPN01530-2.

Explore the full profile